http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2527159-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3059b83559000195f351c509369cd697
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F5-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06
filingDate 2012-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a6cefaa289f55d5d2e3bf27eee4150c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_934ca593f55dd6ace0eea8ce2436fa69
publicationDate 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2527159-C2
titleOfInvention Method for supporting treatment in large joint replacement
abstract FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely traumatology, orthopaedics, and can be used for supporting treatment in large joint replacement. That is ensured by determining a volume of involved joint contracture six months before the operation. That is followed by X-ray and magnetic resonant examination of the involved and collateral joints to specify their state. Besides, a quality of the bone tissue is assessed by osteodensitometry. If observing changes in the bone tissue quality, the complex of the drug therapy is added with the preparations Bivalos and Calcemin. A pain syndrome intensity is assessed by the visual analogue scale three months before the operation. That is followed by the complex therapy aiming at optimising the state of extremity joints with added local injection therapy (LIT). That is ensured by preliminary exposing the biologically active periarticular zones in the proximal and distal direction from the involved joint to the focused infrared laser light. A mixture containing solutions of the therapeutic preparations: chondroprotectors, Contrykal, Lidocaine, vitamin B12 is injected into the same zones. Besides, Arthrofoon is administered for the whole preoperative period. If the pain syndrome intensity is less than 4 points, Arthrofoon is administered in a dose of 4 tablets a day. If the intensity value is more than 4 points, the preparation is administered in a dose of 8 tablets a day in a complex with a short course of a non-steroidal anti-inflammatory preparations and a chondroprotector. The replacement operation is immediately followed by fixing a collateral joint with an orthesis for the period of 3 months. The complex of the postoperative supporting therapy started three weeks after the operation is added with a single intravenous introduction of the preparation Aklasta, the preparation Arthrofoon in a dose of 4 tablets a day for three months, alpha calcidole and Calcemin continuously. A pectoral girdle of the extremities is reinforced by means of an individually specified set of therapeutic exercises and electric walking myostimulation. The LIT of the collateral joint is performed three months after the operation. If observing a degenerative process in the adjacent joints, the LIT is performed alternatively in these regions. Vasodilators, chondroprotectors, and the preparation Milgamma are administered with underlying LIT. If observing psychoemotional changes in the patient, the preparation Tenoten is additionally administered. A postoperative medication regimen, including the LIT is repeated 3-4 times every 6 months. n EFFECT: method provides optimising the effect of the surgical management and preventing developing complications both in the operated joint, and in the adjacent and symmetrical joints after the replacement, preventing developing instability of the endoprosthesis components, preventing developing or aggravating degenerative process in the symmetrical and adjacent joints that reduces a risk of the recurrent operations. n 1 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2693813-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2784348-C1
priorityDate 2012-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2424815-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-62532-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3032771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557728
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12303103
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415712569
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526588
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448905246
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282181
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05205
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01270
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ27IM2
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555252
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407866699
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15502
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01269
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448814769
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5487
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68740
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24694
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22880
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO60109
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396436
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9941750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121837
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP52212
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426586890
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24766
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553004
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4740
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5741
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP11547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121586
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280903
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535486
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2006
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9XT35
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID103183906
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04089
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05700
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3676
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501353
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600743
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GL67
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280805
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453123110
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP54320
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918182
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19147
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99372
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86348
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454112352
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP21948
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81800
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13136
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419589066
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25043
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409406165
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535916
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID19226
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15743
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491555

Total number of triples: 99.